x
|
Quarterly
Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarter Ended June
28, 2008
|
o
|
Transition
Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
|
Delaware
|
04-2209186
|
(State
of incorporation or organization)
|
(I.R.S.
Employer Identification No.)
|
|
|
81
Wyman Street
|
|
Waltham,
Massachusetts
|
02451
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Class
|
|
Outstanding
at June 28, 2008
|
||
Common
Stock, $1.00 par value
|
|
419,013,598
|
June
28,
|
December
31,
|
||||||
(In
millions)
|
2008
|
2007
|
|||||
Assets
|
|||||||
Current
Assets:
|
|||||||
Cash and cash
equivalents
|
$ | 1,006.9 | $ | 625.1 | |||
Short-term
investments, at quoted market value (amortized cost of $13.4 and
$13.6)
|
13.5 | 14.1 | |||||
Accounts receivable, less
allowances of $48.3 and $49.5
|
1,599.1 | 1,450.0 | |||||
Inventories:
|
|||||||
Raw
materials
|
348.4 | 316.5 | |||||
Work in
process
|
117.8 | 118.4 | |||||
Finished
goods
|
797.9 | 735.0 | |||||
Deferred tax
assets
|
167.9 | 195.8 | |||||
Other current
assets
|
248.0 | 210.4 | |||||
4,299.5 | 3,665.3 | ||||||
Property,
Plant and Equipment, at Cost
|
1,851.6 | 1,716.5 | |||||
Less: Accumulated depreciation
and amortization
|
547.1 | 449.1 | |||||
1,304.5 | 1,267.4 | ||||||
Acquisition-related
Intangible Assets, net of Accumulated Amortization of $1,187.5 and
$877.8
|
6,950.2 | 7,157.8 | |||||
Other
Assets
|
408.5 | 403.7 | |||||
Goodwill
|
8,718.3 | 8,713.2 | |||||
$ | 21,681.0 | $ | 21,207.4 |
June
28,
|
December
31,
|
||||||
(In
millions except share amounts)
|
2008
|
2007
|
|||||
Liabilities
and Shareholders’ Equity
|
|||||||
Current
Liabilities:
|
|||||||
Short-term obligations and
current maturities of long-term obligations
|
$ | 145.3 | $ | 149.3 | |||
Accounts
payable
|
653.0 | 676.9 | |||||
Accrued payroll and employee
benefits
|
265.3 | 295.1 | |||||
Accrued income
taxes
|
82.5 | 64.2 | |||||
Deferred
revenue
|
156.4 | 128.5 | |||||
Other accrued
expenses
|
577.6 | 587.6 | |||||
1,880.1 | 1,901.6 | ||||||
Deferred
Income Taxes
|
2,200.0 | 2,279.9 | |||||
Other
Long-term Liabilities
|
486.4 | 491.7 | |||||
Long-term
Obligations
|
2,044.5 | 2,045.9 | |||||
Shareholders’
Equity:
|
|||||||
Preferred
stock, $100 par value, 50,000 shares authorized; none
issued
|
|||||||
Common stock, $1 par value, 1,200,000,000 shares authorized; 445,326,568
and 439,340,851 shares issued
|
445.3 | 439.3 | |||||
Capital in excess of par value
|
12,386.5 | 12,283.4 | |||||
Retained earnings
|
3,017.0 | 2,534.5 | |||||
Treasury stock at cost, 26,312,970 and 24,102,880 shares
|
(1,282.1 | ) | (1,157.3 | ) | |||
Accumulated other comprehensive items
|
503.3 | 388.4 | |||||
15,070.0 | 14,488.3 | ||||||
$ | 21,681.0 | $ | 21,207.4 |
Three
Months Ended
|
|||||||
June
28,
|
June
30,
|
||||||
(In
millions except per share amounts)
|
2008
|
2007
|
|||||
Revenues
|
$ | 2,709.6 | $ | 2,385.9 | |||
Costs
and Operating Expenses:
|
|||||||
Cost of
revenues
|
1,621.5 | 1,449.3 | |||||
Selling, general and
administrative expenses
|
698.9 | 626.6 | |||||
Research and development
expenses
|
64.4 | 58.7 | |||||
Restructuring and other costs
(income), net
|
(5.4 | ) | 8.3 | ||||
2,379.4 | 2,142.9 | ||||||
Operating
Income
|
330.2 | 243.0 | |||||
Other
Expense, Net
|
(22.7 | ) | (20.7 | ) | |||
Income
from Continuing Operations Before Provision for Income
Taxes
|
307.5 | 222.3 | |||||
Provision
for Income Taxes
|
(61.2 | ) | (34.4 | ) | |||
Income
from Continuing Operations
|
246.3 | 187.9 | |||||
Gain (Loss) on Disposal of Discontinued Operations (includes income tax
provision of $1.9 and $1.8)
|
3.2 | (24.0 | ) | ||||
Net
Income
|
$ | 249.5 | $ | 163.9 | |||
Earnings
per Share from Continuing Operations
|
|||||||
Basic
|
$ | .59 | $ | .44 | |||
Diluted
|
$ | .56 | $ | .42 | |||
Earnings
per Share
|
|||||||
Basic
|
$ | .60 | $ | .39 | |||
Diluted
|
$ | .57 | $ | .37 | |||
Weighted
Average Shares
|
|||||||
Basic
|
418.0 | 424.0 | |||||
Diluted
|
437.2 | 446.5 |
Six
Months Ended
|
|||||||
June
28,
|
June
30,
|
||||||
(In
millions except per share amounts)
|
2008
|
2007
|
|||||
Revenues
|
$ | 5,263.6 | $ | 4,724.1 | |||
Costs
and Operating Expenses:
|
|||||||
Cost of
revenues
|
3,157.1 | 2,907.6 | |||||
Selling, general and
administrative expenses
|
1,360.0 | 1,246.9 | |||||
Research and development
expenses
|
126.4 | 118.5 | |||||
Restructuring and other costs
(income), net
|
(0.5 | ) | 15.7 | ||||
4,643.0 | 4,288.7 | ||||||
Operating
Income
|
620.6 | 435.4 | |||||
Other
Expense, Net
|
(35.5 | ) | (47.4 | ) | |||
Income
from Continuing Operations Before Provision for Income
Taxes
|
585.1 | 388.0 | |||||
Provision
for Income Taxes
|
(105.4 | ) | (61.3 | ) | |||
Income
from Continuing Operations
|
479.7 | 326.7 | |||||
Income
from Discontinued Operations (net of income tax provision of $0.1 in
2007)
|
— | 0.1 | |||||
Gain (Loss) on Disposal of Discontinued Operations (includes income tax
provision of $1.9 and $1.8)
|
2.8 | (24.0 | ) | ||||
Net
Income
|
$ | 482.5 | $ | 302.8 | |||
Earnings
per Share from Continuing Operations
|
|||||||
Basic
|
$ | 1.15 | $ | .77 | |||
Diluted
|
$ | 1.10 | $ | .74 | |||
Earnings
per Share
|
|||||||
Basic
|
$ | 1.15 | $ | .72 | |||
Diluted
|
$ | 1.10 | $ | .68 | |||
Weighted
Average Shares
|
|||||||
Basic
|
417.8 | 422.0 | |||||
Diluted
|
436.7 | 443.8 |
Six
Months Ended
|
|||||||
June
28,
|
June
30,
|
||||||
(In
millions)
|
2008
|
2007
|
|||||
Operating
Activities
|
|||||||
Net income
|
$ | 482.5 | $ | 302.8 | |||
Income from discontinued
operations
|
— | (0.1 | ) | ||||
(Gain) Loss on disposal of
discontinued operations
|
(2.8 | ) | 24.0 | ||||
Income from continuing
operations
|
479.7 | 326.7 | |||||
Adjustments
to reconcile income from continuing operations to net cash provided by
operating activities:
|
|||||||
Depreciation and amortization
|
398.6 | 372.4 | |||||
Change in deferred income taxes
|
(60.1 | ) | (10.3 | ) | |||
Noncash equity compensation
|
27.7 | 26.1 | |||||
Noncash charges for sale
of inventories revalued at the date of acquisition
|
0.4 | 47.6 | |||||
Tax benefits from exercised stock options
|
(12.2 | ) | (17.0 | ) | |||
Other noncash expenses, net
|
6.4 | 18.8 | |||||
Changes in assets and
liabilities, excluding the effects of acquisitions and
dispositions:
|
|||||||
Accounts receivable
|
(101.3 | ) | (41.7 | ) | |||
Inventories
|
(64.1 | ) | (57.8 | ) | |||
Other assets
|
(20.3 | ) | (25.6 | ) | |||
Accounts payable
|
(36.9 | ) | (17.2 | ) | |||
Other liabilities
|
(19.1 | ) | (60.7 | ) | |||
Contributions to retirement plans
|
(8.5 | ) | (4.9 | ) | |||
Net cash provided by continuing operations
|
590.3 | 556.4 | |||||
Net cash used in discontinued operations
|
(0.8 | ) | (2.3 | ) | |||
Net cash provided by operating activities
|
589.5 | 554.1 | |||||
Investing
Activities
|
|||||||
Acquisitions, net of cash
acquired
|
(43.0 | ) | (39.1 | ) | |||
Refund of acquisition purchase
price
|
— | 4.6 | |||||
Proceeds from sale of
business
|
3.5 | — | |||||
Proceeds from sale of
available-for-sale investments
|
0.6 | 1.7 | |||||
Purchases of available-for-sale
investments
|
(0.1 | ) | (1.8 | ) | |||
Purchases of property, plant
and equipment
|
(109.3 | ) | (71.8 | ) | |||
Proceeds from sale of property,
plant and equipment
|
5.5 | 14.1 | |||||
Collection of notes
receivable
|
— | 48.2 | |||||
Increase in other
assets
|
(5.2 | ) | (18.3 | ) | |||
Net cash used in continuing operations
|
(148.0 | ) | (62.4 | ) | |||
Net cash provided by discontinued operations
|
0.4 | 28.8 | |||||
Net cash used in investing activities
|
$ | (147.6 | ) | $ | (33.6 | ) |
Six
Months Ended
|
|||||||
June
28,
|
June
30,
|
||||||
(In
millions)
|
2008
|
2007
|
|||||
Financing
Activities
|
|||||||
Decrease in short-term notes
payable
|
$ | (13.4 | ) | $ | (452.5 | ) | |
Purchases of company common
stock
|
(102.0 | ) | — | ||||
Net proceeds from issuance of
company common stock
|
49.1 | 223.6 | |||||
Tax benefits from exercised
stock options
|
12.2 | 17.0 | |||||
Redemption and repayment of
long-term obligations
|
(2.2 | ) | (8.7 | ) | |||
Net cash used in financing activities
|
(56.3 | ) | (220.6 | ) | |||
Exchange
Rate Effect on Cash of Continuing Operations
|
(3.8 | ) | (16.1 | ) | |||
Increase
in Cash and Cash Equivalents
|
381.8 | 283.8 | |||||
Cash
and Cash Equivalents at Beginning of Period
|
625.1 | 667.4 | |||||
Cash
and Cash Equivalents at End of Period
|
$ | 1,006.9 | $ | 951.2 | |||
Supplemental
Cash Flow Information
|
|||||||
Fair value of assets of
acquired businesses
|
$ | 53.7 | $ | 39.8 | |||
Cash paid for acquired
businesses
|
(31.5 | ) | (30.8 | ) | |||
Liabilities assumed of
acquired businesses
|
$ | 22.2 | $ | 9.0 | |||
Conversion of subordinated
convertible debentures
|
$ | — | $ | 0.4 | |||
Issuance of restricted
stock
|
$ | 21.3 | $ | 0.2 | |||
Issuance of stock upon vesting
of restricted stock units
|
$ | 19.3 | $ | 16.1 |
1.
|
General
|
2.
|
Acquisitions
|
2.
|
Acquisitions
(continued)
|
(In
millions)
|
Total
|
|||
Purchase
Price:
|
||||
Cash Paid Including Transaction
Costs
|
$ | 32.4 | ||
Debt Assumed
|
7.7 | |||
Cash Acquired
|
(0.9 | ) | ||
$ | 39.2 | |||
Allocation:
|
||||
Current assets
|
$ | 19.1 | ||
Property, plant and
equipment
|
6.1 | |||
Customer
relationships
|
8.1 | |||
Product
technology
|
3.3 | |||
Tradenames and
other
|
6.3 | |||
Goodwill
|
10.6 | |||
Other assets
|
0.2 | |||
Liabilities
assumed
|
(14.5 | ) | ||
$ | 39.2 |
(In millions) |
Severance
|
Abandonment
of Excess
Facilities
|
Other
|
Total
|
|||||||||||
Balance
at December 31, 2007
|
$ | 3.6 | $ | 5.5 | $ | 0.4 | $ | 9.5 | |||||||
Reserves
established
|
0.1 | 0.4 | — | 0.5 | |||||||||||
Payments
|
(0.4 | ) | (1.4 | ) | (0.1 | ) | (1.9 | ) | |||||||
Decrease
recorded as a reduction in goodwill
|
(1.4 | ) | (0.6 | ) | (0.2 | ) | (2.2 | ) | |||||||
Currency
translation
|
— | (0.1 | ) | — | (0.1 | ) | |||||||||
Balance
at June 28, 2008
|
$ | 1.9 | $ | 3.8 | $ | 0.1 | $ | 5.8 |
2.
|
Acquisitions
(continued)
|
3.
|
Business
Segment Information
|
Three
Months Ended
|
Six
Months Ended
|
||||||||||||
June
28,
|
June
30,
|
June
28,
|
June
30,
|
||||||||||
(In
millions)
|
2008
|
2007
|
2008
|
2007
|
|||||||||
Revenues
|
|||||||||||||
Analytical
Technologies
|
$ | 1,160.6 | $ | 1,020.4 | $ | 2,248.0 | $ | 2,008.7 | |||||
Laboratory Products and
Services
|
1,656.4 | 1,449.7 | 3,224.8 | 2,883.2 | |||||||||
Eliminations
|
(107.4 | ) | (84.2 | ) | (209.2 | ) | (167.8 | ) | |||||
Consolidated revenues
|
$ | 2,709.6 | $ | 2,385.9 | $ | 5,263.6 | $ | 4,724.1 | |||||
Operating
Income
|
|||||||||||||
Analytical Technologies
(a)
|
$ | 245.1 | $ | 201.9 | $ | 473.8 | $ | 387.3 | |||||
Laboratory Products and
Services (a)
|
231.5 | 202.7 | 449.9 | 392.8 | |||||||||
Subtotal reportable
segments (a)
|
476.6 | 404.6 | 923.7 | 780.1 | |||||||||
Cost of revenues
charges
|
(0.2 | ) | (11.2 | ) | (0.8 | ) | (47.6 | ) | |||||
Restructuring and other income
(costs), net
|
5.4 | (8.3 | ) | 0.5 | (15.7 | ) | |||||||
Amortization of
acquisition-related intangible assets
|
(151.6 | ) | (142.1 | ) | (302.8 | ) | (281.4 | ) | |||||
Consolidated operating
income
|
330.2 | 243.0 | 620.6 | 435.4 | |||||||||
Other expense, net
(b)
|
(22.7 | ) | (20.7 | ) | (35.5 | ) | (47.4 | ) | |||||
Income from continuing
operations before provision for income taxes
|
$ | 307.5 | $ | 222.3 | $ | 585.1 | $ | 388.0 | |||||
Depreciation
|
|||||||||||||
Analytical
Technologies
|
$ | 22.5 | $ | 20.2 | $ | 44.3 | $ | 40.5 | |||||
Laboratory Products and
Services
|
25.7 | 24.8 | 51.5 | 50.5 | |||||||||
Consolidated
depreciation
|
$ | 48.2 | $ | 45.0 | $ | 95.8 | $ | 91.0 |
(a)
|
Represents
operating income before certain charges to cost of revenues; restructuring
and other costs, net and amortization of acquisition-related
intangibles.
|
(b)
|
The
company does not allocate other income and expenses to its
segments.
|
4.
|
Other
Expense, Net
|
Three
Months Ended
|
Six
Months Ended
|
||||||||||||
June
28,
|
June
30,
|
June
28,
|
June
30,
|
||||||||||
(In
millions)
|
2008
|
2007
|
2008
|
2007
|
|||||||||
Interest
Income
|
$ | 15.1 | $ | 10.6 | $ | 25.2 | $ | 19.5 | |||||
Interest
Expense
|
(36.6 | ) | (33.2 | ) | (67.0 | ) | (70.4 | ) | |||||
Other
Items, Net
|
(1.2 | ) | 1.9 | 6.3 | 3.5 | ||||||||
$ | (22.7 | ) | $ | (20.7 | ) | $ | (35.5 | ) | $ | (47.4 | ) |
5.
|
Earnings
per Share
|
Three
Months Ended
|
Six
Months Ended
|
||||||||||||
June
28,
|
June
30,
|
June
28,
|
June
30,
|
||||||||||
(In
millions except per share amounts)
|
2008
|
2007
|
2008
|
2007
|
|||||||||
Income
from Continuing Operations
|
$ | 246.3 | $ | 187.9 | $ | 479.7 | $ | 326.7 | |||||
Income
from Discontinued Operations
|
— | — | — | 0.1 | |||||||||
Gain (Loss) on Disposal of Discontinued Operations
|
3.2 | (24.0 | ) | 2.8 | (24.0 | ) | |||||||
Income
Available to Common Shareholders
|
$ | 249.5 | $ | 163.9 | $ | 482.5 | $ | 302.8 | |||||
Basic
Weighted Average Shares
|
418.0 | 424.0 | 417.8 | 422.0 | |||||||||
Effect
of:
|
|||||||||||||
Convertible
debentures
|
15.5 | 13.7 | 15.1 | 12.7 | |||||||||
Stock options, restricted stock
awards and warrants
|
3.7 | 8.8 | 3.8 | 9.1 | |||||||||
Diluted
Weighted Average Shares
|
437.2 | 446.5 | 436.7 | 443.8 | |||||||||
Basic
Earnings per Share
|
|||||||||||||
Continuing
operations
|
$ | .59 | $ | .44 | $ | 1.15 | $ | .77 | |||||
Discontinued
operations
|
.01 | (.06 | ) | .01 | (.06 | ) | |||||||
$ | .60 | $ | .39 | $ | 1.15 | $ | .72 | ||||||
Diluted
Earnings per Share
|
|||||||||||||
Continuing
operations
|
$ | .56 | $ | .42 | $ | 1.10 | $ | .74 | |||||
Discontinued
operations
|
.01 | (.05 | ) | .01 | (.05 | ) | |||||||
$ | .57 | $ | .37 | $ | 1.10 | $ | .68 |
6.
|
Comprehensive
Income
|
7.
|
Stock-based
Compensation Expense
|
Three
Months Ended
|
Six
Months Ended
|
||||||||||||
June
28,
|
June
30,
|
June
28,
|
June
30,
|
||||||||||
(In
millions)
|
2008
|
2007
|
2008
|
2007
|
|||||||||
Stock
Option Awards
|
$ | 9.3 | $ | 8.3 | $ | 16.0 | $ | 17.6 | |||||
Restricted
Share/Unit Awards
|
7.4 | 4.0 | 11.7 | 8.5 | |||||||||
Total
Stock-based Compensation Expense
|
$ | 16.7 | $ | 12.3 | $ | 27.7 | $ | 26.1 |
Three
Months Ended
|
Six
Months Ended
|
||||||||||||
June
28,
|
June
30,
|
June
28,
|
June
30,
|
||||||||||
(In
millions)
|
2008
|
2007
|
2008
|
2007
|
|||||||||
Cost
of Revenues
|
$ | 0.9 | $ | 0.8 | $ | 2.0 | $ | 2.1 | |||||
Selling,
General and Administrative Expenses
|
15.3 | 10.9 | 24.9 | 22.9 | |||||||||
Research
and Development Expenses
|
0.5 | 0.6 | 0.8 | 1.1 | |||||||||
Total
Stock-based Compensation Expense
|
$ | 16.7 | $ | 12.3 | $ | 27.7 | $ | 26.1 |
8.
|
Defined
Benefit Pension Plans
|
Three
Months Ended
|
Six
Months Ended
|
||||||||||||
June
28,
|
June
30,
|
June
28,
|
June
30,
|
||||||||||
(In
millions)
|
2008
|
2007
|
2008
|
2007
|
|||||||||
Service
Cost
|
$ | 3.4 | $ | 4.1 | $ | 7.7 | $ | 8.2 | |||||
Interest
Cost on Benefit Obligation
|
14.3 | 14.0 | 28.8 | 27.9 | |||||||||
Expected
Return on Plan Assets
|
(15.9 | ) | (14.7 | ) | (31.7 | ) | (29.3 | ) | |||||
Amortization
of Net Loss
|
0.4 | 0.9 | 0.8 | 1.8 | |||||||||
Curtailment
Gain
|
(18.5 | ) | — | (18.5 | ) | — | |||||||
Special
Termination Benefits
|
0.2 | — | 0.2 | — | |||||||||
Net
Periodic Benefit Cost (Income)
|
$ | (16.1 | ) | $ | 4.3 | $ | (12.7 | ) | $ | 8.6 |
Three
Months Ended
|
Six
Months Ended
|
||||||||||||
June
28,
|
June
30,
|
June
28,
|
June
30,
|
||||||||||
(In
millions)
|
2008
|
2007
|
2008
|
2007
|
|||||||||
Service
Cost
|
$ | 0.2 | $ | 0.2 | $ | 0.4 | $ | 0.4 | |||||
Interest
Cost on Benefit Obligation
|
0.5 | 0.4 | 1.0 | 0.8 | |||||||||
Net
Periodic Benefit Cost
|
$ | 0.7 | $ | 0.6 | $ | 1.4 | $ | 1.2 |
9.
|
Fair
Value Measurements
|
9.
|
Fair
Value Measurements (continued)
|
Description
|
June
28, 2008
|
Quoted
Prices in
Active
Markets
(Level
1)
|
Significant
Other
Observable
Inputs
(Level
2)
|
Significant
Unobservable
Inputs
(Level
3)
|
|||||||||
Assets
|
|||||||||||||
Cash
equivalents
|
$ | 529.8 | $ | 529.8 | $ | — | $ | — | |||||
Investments in mutual
funds, unit trusts and other similar instruments
|
33.7 | 33.7 | — | — | |||||||||
Cash surrender value of
life insurance
|
18.2 | — | 18.2 | — | |||||||||
Auction rate
securities
|
7.9 | — | 7.9 | — | |||||||||
Interest rate
swap
|
1.0 | — | 1.0 | — | |||||||||
Marketable equity
securities
|
2.7 | 2.7 | — | — | |||||||||
Derivatives
|
0.9 | — | 0.9 | — | |||||||||
Total
Assets
|
$ | 594.2 | $ | 566.2 | $ | 28.0 | $ | — | |||||
Liabilities
|
|||||||||||||
Derivatives
|
$ | 0.7 | $ | — | $ | 0.7 | $ | — | |||||
Total
Liabilities
|
$ | 0.7 | $ | — | $ | 0.7 | $ | — |
10.
|
Warranty
Obligations
|
Six
Months Ended
|
|||||||
June
28,
|
June
30,
|
||||||
(In
millions)
|
2008
|
2007
|
|||||
Beginning
Balance
|
$ | 50.6 | $ | 45.5 | |||
Provision
charged to income
|
19.2 | 21.8 | |||||
Usage
|
(19.5 | ) | (18.8 | ) | |||
Acquisitions/divestitures
|
— | 0.6 | |||||
Adjustments
to previously provided warranties, net
|
(0.9 | ) | — | ||||
Other,
net (a)
|
1.8 | 1.1 | |||||
Ending
Balance
|
$ | 51.2 | $ | 50.2 |
(a)
|
Primarily
represents the effects of currency
translation.
|
11.
|
Restructuring
and Other Costs, Net
|
(In
millions)
|
Analytical
Technologies
|
Laboratory
Products
and
Services
|
Corporate
|
Total
|
|||||||||
Cost
of Revenues
|
$ | 0.2 | $ | — | $ | — | $ | 0.2 | |||||
Restructuring
and Other Costs, Net
|
11.8 | 0.6 | (17.8 | ) | (5.4 | ) | |||||||
$ | 12.0 | $ | 0.6 | $ | (17.8 | ) | $ | (5.2 | ) |
(In
millions)
|
Analytical
Technologies
|
Laboratory
Products
and
Services
|
Corporate
|
Total
|
|||||||||
Cost
of Revenues
|
$ | 0.5 | $ | 0.3 | $ | — | $ | 0.8 | |||||
Restructuring
and Other Costs, Net
|
14.1 | 1.4 | (16.0 | ) | (0.5 | ) | |||||||
$ | 14.6 | $ | 1.7 | $ | (16.0 | ) | $ | 0.3 |
11.
|
Restructuring
and Other Costs, Net (continued)
|
11.
|
Restructuring
and Other Costs, Net (continued)
|
(In
millions)
|
Severance
|
Employee
Retention
(a)
|
Abandonment
of
Excess
Facilities
|
Other
|
Total
|
|||||||||||
Pre-2007
Restructuring Plans
|
||||||||||||||||
Balance at December 31,
2007
|
$ | 1.8 | $ | — | $ | 3.6 | $ | 0.6 | $ | 6.0 | ||||||
Costs incurred in 2008
(b)
|
0.6 | — | 0.7 | 0.1 | 1.4 | |||||||||||
Reserves
reversed
|
(0.1 | ) | — | — | — | (0.1 | ) | |||||||||
Payments
|
(1.1 | ) | — | (1.4 | ) | (0.1 | ) | (2.6 | ) | |||||||
Currency
translation
|
0.1 | — | 0.2 | — | 0.3 | |||||||||||
Balance at June 28,
2008
|
$ | 1.3 | $ | — | $ | 3.1 | $ | 0.6 | $ | 5.0 | ||||||
2007
Restructuring Plans
|
||||||||||||||||
Balance at December 31,
2007
|
$ | 9.2 | $ | 1.5 | $ | 1.1 | $ | 1.6 | $ | 13.4 | ||||||
Costs incurred in 2008
(b)
|
2.4 | 0.9 | 1.3 | 0.9 | 5.5 | |||||||||||
Reserves
reversed
|
(0.4 | ) | (0.4 | ) | (0.1 | ) | — | (0.9 | ) | |||||||
Payments
|
(4.8 | ) | (1.3 | ) | (1.0 | ) | (1.5 | ) | (8.6 | ) | ||||||
Currency
translation
|
0.5 | 0.1 | 0.1 | 0.1 | 0.8 | |||||||||||
Balance at June 28,
2008
|
$ | 6.9 | $ | 0.8 | $ | 1.4 | $ | 1.1 | $ | 10.2 | ||||||
2008
Restructuring Plans
|
||||||||||||||||
Costs incurred in 2008
(b)
|
$ | 4.8 | $ | 0.1 | $ | 0.2 | $ | 1.1 | $ | 6.2 | ||||||
Payments
|
(2.0 | ) | — | (0.2 | ) | (1.0 | ) | (3.2 | ) | |||||||
Balance at June 28,
2008
|
$ | 2.8 | $ | 0.1 | $ | — | $ | 0.1 | $ | 3.0 |
(a)
|
Employee-retention
costs are accrued ratably over the period through which employees must
work to qualify for a payment.
|
(b)
|
Excludes
non-cash items, including an $18.5 million gain on the curtailment of a
pension plan in the U.S., a $5.0 million loss associated with a
litigation-related matter assumed as part of the merger with Fisher in
2006, a $3.0 million loss related to the sale of a business, a $1.8
million gain on the sale of real estate and $0.3 million of other non-cash
income, net.
|
12.
|
Litigation
and Related Contingencies
|
12.
|
Litigation
and Related Contingencies
(continued)
|
13.
|
Recent
Accounting Pronouncements
|
Item
2.
|
Management’s
Discussion and Analysis of Financial Condition and Results of
Operations
|
Three
Months Ended
|
Six
Months Ended
|
||||||||||||||||||||
(Dollars in millions) |
June
28, 2008
|
June
30, 2007
|
June
28, 2008
|
June
30, 2007
|
|||||||||||||||||
Analytical
Technologies
|
$ | 1,160.6 | 42.8% | $ | 1,020.4 | 42.8% | $ | 2,248.0 | 42.7% | $ | 2,008.7 | 42.5% | |||||||||
Laboratory
Products and Services
|
1,656.4 | 61.1% | 1,449.7 | 60.8% | 3,224.8 | 61.3% | 2,883.2 | 61.0% | |||||||||||||
Eliminations
|
(107.4 | ) | (3.9)% | (84.2 | ) | (3.6)% | (209.2 | ) | (4.0)% | (167.8 | ) | (3.5)% | |||||||||
$ | 2,709.6 | 100% | $ | 2,385.9 | 100% | $ | 5,263.6 | 100% | $ | 4,724.1 | 100% |
Three
Months Ended
|
|||||||||
June
28,
|
June
30,
|
||||||||
(Dollars in millions) |
2008
|
2007
|
Change
|
||||||
Revenues
|
|||||||||
Analytical
Technologies
|
$ | 1,160.6 | $ | 1,020.4 | 14% | ||||
Laboratory Products and
Services
|
1,656.4 | 1,449.7 | 14% | ||||||
Eliminations
|
(107.4 | ) | (84.2 | ) | |||||
Consolidated
Revenues
|
$ | 2,709.6 | $ | 2,385.9 | 14% | ||||
Operating
Income
|
|||||||||
Analytical
Technologies
|
$ | 245.1 | $ | 201.9 | 21% | ||||
Laboratory Products and Services
|
231.5 | 202.7 | 14% | ||||||
Subtotal Reportable
Segments
|
476.6 | 404.6 | 18% | ||||||
Cost of Revenues
Charges
|
(0.2 | ) | (11.2 | ) | |||||
Restructuring and Other
Income (Costs), Net
|
5.4 | (8.3 | ) | ||||||
Amortization of
Acquisition-related Intangible Assets
|
(151.6 | ) | (142.1 | ) | |||||
Consolidated Operating
Income
|
$ | 330.2 | $ | 243.0 | 36% |
Three
Months Ended
|
|||||||||
June
28,
|
June
30,
|
||||||||
(Dollars in millions) |
2008
|
2007
|
Change
|
||||||
Revenues
|
$ | 1,160.6 | $ | 1,020.4 | 14% | ||||
Operating
Income Margin
|
21.1% | 19.8% |
1.3 pts.
|
Three
Months Ended
|
|||||||||
June
28,
|
June
30,
|
||||||||
(Dollars in millions) |
2008
|
2007
|
Change
|
||||||
Revenues
|
$ | 1,656.4 | $ | 1,449.7 | 14% | ||||
Operating
Income Margin
|
14.0% | 14.0% |
— pts.
|
Six
Months Ended
|
|||||||||
June
28,
|
June
30,
|
||||||||
(Dollars in millions) |
2008
|
2007
|
Change
|
||||||
Revenues
|